NCT07074002View on ClinicalTrials.gov

Proof of Concept Study on BP1.4979 Effect on Essential Tremor

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

50

Participants

Timeline

Start Date

July 31, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions

Essential Tremor

Interventions

DRUG

BP1.4979

Selective dopamine D3 partial agonist

DRUG

Placebo

Matching placebo of BP1.4979 tablet

Trial Locations (1)

59037

CHU de Lille - Hôpital Roger SALENGRO, Lille

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Bioprojet

OTHER